Get started
Author

Gerard T. Harty

Observed names: G Harty, G. Harty, G. T. Harty, G., Harty, GT Harty, Gerard Harty, Gerard T Harty, Harty, G. (Gerard), Harty, Gerard, Harty, Gerard T.
ORCID: 0000-0002-1986-4760
Observed ORCID: 0000-0002-1986-4760
OpenAlex ID: A5028167219
Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing–remitting multiple sclerosis
2017 · Mohd Kashif Siddiqui, Inderpreet Singh Khurana, et al. · Current Medical Research and Opinion · 85
PDF
Summarizing Patient Preferences for the Competitive Landscape of Multiple Sclerosis Treatment Options
2020 · Marcel F. Jonker, Bas Donkers, et al. · Medical Decision Making · 44
PDF
Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England
2018 · Robert Hettle, Gerard Harty, et al. · Journal of Medical Economics · 42
Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing–remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches
2019 · Andrea Berardi, Mohd Kashif Siddiqui, et al. · Current Medical Research and Opinion · 24
Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work
2018 · Gerard Harty, James Jarrett, et al. · Applied Health Economics and Health Policy · 18
PDF
Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
2019 · Renée Else Michels, Maria de Fransesco, et al. · Applied Health Economics and Health Policy · 16
PDF
The value of treatment for infertility: A systematic literature review of willingness-to-pay thresholds and approaches for determining the cost effectiveness of fertility therapies
2023 · Elisabeth Fenwick, Adaeze Eze, et al. · Best Practice & Research Clinical Obstetrics & Gynaecology · 14
Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment
2020 · Patrick Vermersch, Andrew Galazka, et al. · Current Medical Research and Opinion · 14
PDF
Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study
2023 · Wallace J. Brownlee, Aiden Haghikia, et al. · Multiple Sclerosis and Related Disorders · 11
PDF
Cost Effectiveness Of Cetuximab In First Line Treatment Of Ras Wild-Type Metastatic Colorectal Cancer In The Uk: A Summary Of Economic Analyses Submitted To The National Institute For Health And Care Excellence (Nice)
2015 · A Hnoosh, GT Harty, et al. · Value in Health · 10
PDF
Modified Delphi study of decision‐making around treatment sequencing in relapsing–remitting multiple sclerosis
2020 · M. A. Piena, O. Schoeman, et al. · European Journal of Neurology · 9
Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing–Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study
2019 · Helen Bell Gorrod, Nicholas R. Latimer, et al. · Value in Health · 7
Use of rituximab in adults with relapsing–remitting multiple sclerosis: a systematic literature review
2020 · Mohd Kashif Siddiqui, Barinder Singh, et al. · Current Medical Research and Opinion · 6
Desirability and acceptability of a treatment-sequencing model in relapsing-remitting multiple sclerosis: A health technology assessment perspective
2020 · Marjanne A. Piena, Olaf Schoeman, et al. · International Journal of Technology Assessment in Health Care · 4
Cost Effectiveness of Cetuximab in 1st-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer in Scotland: A Summary of the Submission to the Scottish Medicines Consortium
2014 · J. Jarrett, O. Ovcinnikova, et al. · Value in Health · 4
An Innovative Approach to Modelling the Optimal Treatment Sequence for Patients with Relapsing–Remitting Multiple Sclerosis: Implementation, Validation, and Impact of the Decision-Making Approach
2021 · Marjanne A. Piena, Sonja Kroep, et al. · Advances in Therapy · 3
PDF
Consequences Of Biomarker Analysis On The Cost-Effectiveness Of Cetuximab In Combination With Irinotecan Based Chemotherapy For First-Line Treatment Of Metastatic Colorectal Cancer. Stratified Medicine At Work?
2015 · GT Harty, J Jarrett, et al. · Value in Health · 3
Updated systematic literature review and network meta-analysis of cladribine tablets versus currently approved disease-modifying treatments for active relapsing-remitting multiple sclerosis
2026 · Gerard T. Harty, Michelle Jones, et al. · Multiple Sclerosis and Related Disorders · 2
PDF
Comparative Effectiveness of Cladribine versus Fingolimod in the Treatment of Highly Active Relapsing Multiple Sclerosis: The MERLYN (MavEnclad Real worLd comparative efficacY non-iNterventional) Study (P7-4.005)
2022 · Wallace Brownlee, Aiden Haghikia, et al. · Neurology · 2
Efficiency Model of Cladribine Tablets Versus Infusion-Based Disease-Modifying Drugs for Patients with Relapsing-Remitting Multiple Sclerosis
2020 · Ali Tafazzoli, Ameya Chavan, et al. · Advances in Therapy · 2
Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods
2019 · Helen Bell Gorrod, Nicholas R. Latimer, et al. · Advances in Therapy · 2
The comparative efficacy of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis: Updated meta-regression estimates by patient subgroup
2026 · Gerard T Harty, Michelle Jones, et al. · Multiple Sclerosis and Related Disorders · 1
A Cost-Effectiveness Analysis of Gonadotropins Used for Ovarian Stimulation during Assisted Reproductive Technology Based on Data from the French Nationwide Claims Database (SNDS)
2024 · Isabelle Borget, Mehdi Benchaib, et al. · Gynecologic and Obstetric Investigation · 1
PDF
The Effect of Cladribine Tablets in People With More Active Multiple Sclerosis: A Plain Language Summary
2022 · Patrick Vermersch, Andrew Galazka, et al. · Neurodegenerative Disease Management · 1
Discontinuation of Disease-modifying Treatments in Relapsing-remitting Multiple Sclerosis – A Systematic Literature Review of Observational Studies
2019 · Gerard T Harty, Schiffon L Wong, et al. · European Neurological Review · 1
PDF
Works count: 55
Citation count: 331
H-index: 10
I10-index: 10
Year
Topic
Type